The invention relates to cocrystals of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide (Apremilast) with caffeine (APM-CAF) and 4-hydroxybenzoic acid (APM-4HB). It also refers to pharmaceutical compositions and dosage forms comprising said cocrystals. The invention also concerns said pharmaceutical compositions or dosage forms for use in a method of treating a disease or disorder defined in the claims. Finally, the invention pertains to the use of said cocrystals for the preparation of pharmaceutical compositions and dosage forms.
